<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Headache during pregnancy and postpartum</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Headache during pregnancy and postpartum</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Headache during pregnancy and postpartum</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Men-Jean Lee, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Debra Guinn, MD, FACOG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan Hickenbottom, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Headache is common among females in their childbearing years: In the Norwegian Head-HUNT study, 60 percent of females ≤40 years of age reported experiencing a headache within the previous year [<a href="#rid1">1</a>]. For patients with a history of headache, the effect of pregnancy on the frequency and severity of headache, the effect of headache on pregnancy outcome, and the fetal safety of maternal headache treatment are major concerns. For patients with new onset of headache during pregnancy or postpartum, a diagnostic evaluation is indicated and should include evaluation for pregnancy-related causes of headache. Preeclampsia with severe features always needs to be excluded in pregnant patients over 20 weeks of gestation with a headache.</p><p>This topic will discuss issues specific to diagnosis and management of headache in pregnant and postpartum patients. The diagnosis and treatment of headaches in the general population are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3349.html" rel="external">"Evaluation of headache in adults"</a> and  <a class="medical medical_review" href="/z/d/html/287.html" rel="external">"Evaluation of the adult with nontraumatic headache in the emergency department"</a>.)</p><p class="headingAnchor" id="H305898571"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H2096888321"><span class="h2">Patients requiring prompt evaluation</span></p><p class="headingAnchor" id="H503172169"><span class="h3">Patients ≥20 weeks of gestation (evaluate for preeclampsia)</span><span class="headingEndMark"> — </span>Preeclampsia must be considered in every pregnant patient over 20 weeks of gestation with headache. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Among pregnant patients with no history of a headache and the onset of new or atypical headache who present for evaluation, one-third have preeclampsia [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic criteria</strong> – Criteria for diagnosis of preeclampsia are described in the table and form the basis for evaluation  (<a class="graphic graphic_table graphicRef79977" href="/z/d/graphic/79977.html" rel="external">table 1</a>). The diagnosis can be excluded in most normotensive patients. (See  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical findings</strong> – Headache is a feature of the severe spectrum of preeclamptic disease and a potential precursor of eclampsia (preeclampsia with seizure) [<a href="#rid3">3</a>]. The headache is typically diffuse (holocephalic), constant, throbbing, and mild to severe in intensity. Blurred vision, photophobia, and confusion and alteration in the level of consciousness may occur. These symptoms are similar to those of migraine, except migraine pain is frequently unilateral. In patients with mildly increased blood pressure that may be due to pain, the diagnosis of preeclampsia-related headache is supported by the presence of other severe features of the disease: scotomata or other visual problems (eg, blurred vision, double vision, photophobia, amaurosis, hemianopsia), epigastric pain, or laboratory findings of thrombocytopenia, elevated liver chemistries, hemolysis, and/or elevated creatinine. </p><p></p><p class="bulletIndent1">The neurologic examination is usually normal in preeclampsia. Focal neurologic symptoms suggest complicated preeclampsia (eg, stroke) or an alternative diagnosis (eg, migraine with aura, stroke unrelated to preeclampsia). Although seizure is the key finding of eclampsia, it also occurs with other intracranial pathology, including cerebral venous thrombosis, hemorrhage, and tumor. (See  <a class="medical medical_review" href="/z/d/html/1662.html" rel="external">"Eclampsia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – The cause of headache in preeclampsia/eclampsia is not known, but may be related to increased cerebral perfusion pressure (eg, hypertensive encephalopathy) [<a href="#rid4">4,5</a>], cerebral ischemia from vasoconstriction (reversible cerebral vasoconstriction syndrome [RCVS]) [<a href="#rid4">4</a>], posterior reversible encephalopathy syndrome (PRES) [<a href="#rid6">6</a>], cerebral edema, or microhemorrhages [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/1108.html" rel="external">"Cerebrovascular disorders complicating pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Consultation</strong> – Patients in whom preeclampsia/eclampsia is suspected should have an obstetric or maternal-fetal medicine consultation. A neurologist or neurosurgeon should be consulted in those with an abnormal neurologic examination or severe headache that persists after preeclampsia/eclampsia has been excluded. </p><p></p><p class="headingAnchor" id="H3468526460"><span class="h3">Patients with symptoms potentially associated with a serious underlying disorder</span><span class="headingEndMark"> — </span>Pregnant patients with the following signs/symptoms associated with headache are more likely to have a serious underlying disorder that may or may not be related to pregnancy and requires prompt intervention. These patients should have a complete neurologic evaluation by a clinician experienced in this examination. A reasonable approach is illustrated by the following algorithm  (<a class="graphic graphic_algorithm graphicRef107496" href="/z/d/graphic/107496.html" rel="external">algorithm 1</a>) and discussed in detail separately (see  <a class="medical medical_review" href="/z/d/html/3349.html" rel="external">"Evaluation of headache in adults"</a>). Cerebral venous thrombosis and stroke are examples of disorders that are more common in pregnant/postpartum patients. (See  <a class="medical medical_review" href="/z/d/html/1108.html" rel="external">"Cerebrovascular disorders complicating pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Headache with altered mental status, seizures, papilledema, changes in vision, stiff neck, or focal neurological signs/symptoms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sudden onset of severe headache</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New-onset of migraine-type headache (eg, unilateral, throbbing or pulsatile quality with nausea, vomiting, photophobia or phonophobia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Headache in an immunosuppressed individual</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Change in headache characteristics (eg, pain, pattern, severity) from usual headaches</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Headache associated with/precipitated by fever, head trauma, illicit drug use or toxic exposure, cough, exertion, sexual activity, or Valsalva maneuver</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Headache of new onset that awakens the patient from sleep</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Headache unrelieved by pain medication</p><p></p><p class="headingAnchor" id="H4209345955"><span class="h2">General approach to evaluating headache in pregnancy</span><span class="headingEndMark"> — </span>Most pregnant patients with primary headache syndromes (tension-type headache, migraine headache, cluster headache) have been diagnosed before pregnancy [<a href="#rid2">2</a>]. A patient with a prior history of headache may continue to experience headache during pregnancy; pursuing a complicated duplication of diagnostic testing is not necessary if their characteristic symptoms have not changed and preeclampsia has been excluded.</p><p>Among pregnant patients with the onset of new or atypical headache in whom preeclampsia has been excluded, approximately half have migraine and the other half have a variety of other causes of headache  (<a class="graphic graphic_table graphicRef71620" href="/z/d/graphic/71620.html" rel="external">table 2</a>) [<a href="#rid8">8,9</a>]. These patients should be evaluated initially with a detailed history and physical examination [<a href="#rid10">10</a>]. The diagnostic evaluation is similar to that in nonpregnant adults (see  <a class="medical medical_review" href="/z/d/html/3349.html" rel="external">"Evaluation of headache in adults"</a>), and should be initiated promptly in those with signs/symptoms of a serious underlying disorder. (See <a class="local">'Patients with symptoms potentially associated with a serious underlying disorder'</a> above.)</p><p>Migraine, tension-type, and cluster headaches are diagnosed by specific clinical criteria  (<a class="graphic graphic_table graphicRef68064" href="/z/d/graphic/68064.html" rel="external">table 3</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3326.html" rel="external">"Cluster headache: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p>A general approach to the evaluation of new headache is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef141075" href="/z/d/graphic/141075.html" rel="external">algorithm 2</a>). Clinical features of headaches related to underlying conditions are described in the table  (<a class="graphic graphic_table graphicRef141069" href="/z/d/graphic/141069.html" rel="external">table 4</a>). </p><p class="headingAnchor" id="H4102656502"><span class="h2">Evaluation of postpartum patients</span><span class="headingEndMark"> — </span>The postpartum period is characterized by hormonal and other physiological changes, sleep deprivation, irregular food intake, psychological stress, and fatigue. In addition, many patients have had a neuraxial anesthetic for labor and delivery or have been given vasoactive drugs (eg, ergots). These are all risk factors for development of headache. The following basic guidelines apply to the evaluation of patients with postpartum headache [<a href="#rid11">11,12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Preeclampsia should be the initial consideration in patients with hypertension. Preeclampsia can present postpartum, usually within 48 hours of delivery, but sometimes a week or more postpartum. (See <a class="local">'Patients ≥20 weeks of gestation (evaluate for preeclampsia)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of worrisome signs/symptoms, such as new focal neurologic findings, warrants consultation with a neurologist. (See  <a class="medical medical_review" href="/z/d/html/1108.html" rel="external">"Cerebrovascular disorders complicating pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient is normotensive and had neuraxial anesthesia for labor/delivery, an anesthesiologist or neurologist should be consulted for evaluation and treatment of postdural puncture headache (PDPH). The pain in PDPH typically develops within 48 hours of the procedure and is worse on standing or raising the head from the bed and characteristically improves with rest in a supine position; tinnitus, nausea, vomiting, and cranial nerve dysfunction rarely occur. (See  <a class="medical medical_review" href="/z/d/html/113316.html" rel="external">"Post dural puncture headache"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tension-type headache is the likely diagnosis in patients without focal neurologic deficits or findings consistent with preeclampsia. Migraine headache with or without aura is also common in this setting, especially in patients with a history of migraine (see <a class="local">'Migraine'</a> below and <a class="local">'Tension-type headache'</a> below). Cluster headache is rare (see <a class="local">'Cluster headache'</a> below). These headaches are diagnosed according to standard criteria from the International Classification for Headache Disorders (ICHD)  (<a class="graphic graphic_table graphicRef68064" href="/z/d/graphic/68064.html" rel="external">table 3</a>).</p><p></p><p>Although headache is common postpartum, the prevalence across studies varies widely depending on the definitions used, method of ascertainment (eg, discharge diagnosis, postal survey, patient evaluation), timing (two to four days postpartum to one year after delivery), and patient population (eg, breastfeeding status). </p><p>The range and frequency of etiologies in different postpartum populations is illustrated by the following examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort study in which most of the 381 postpartum patients had mild or moderate headache pain, the most common etiologies were tension-type, migraine, and musculoskeletal/cervicogenic [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 95 postpartum patients with severe unrelenting headache greater than 24 hours and less than 42 days from the time of delivery, the types and frequencies of headache were tension-type (39 percent), preeclampsia/eclampsia (24 percent), postdural puncture (16 percent), migraine (11 percent), pituitary hemorrhage/mass (3 percent), cerebral venous thrombosis (3 percent), and other (4 percent) [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective review of 63 consecutive postpartum patients who presented to the obstetric or emergency service with acute postpartum headache and were seen in consultation by the neurology service, 27 percent (17/63) had a primary headache disorder (most commonly migraine [13]) and 73 percent (46/63) had a secondary headache disorder (postdural puncture headache [21], preeclampsia [12], pituitary apoplexy [2], cerebral venous thrombosis [1], Moyamoya [1], RCVS [3], posterior reversible encephalopathy syndrome (PRES)[2], vertebral artery dissection [1], medication related headache [2], anemia related headache [1]) [<a href="#rid13">13</a>].</p><p></p><p class="headingAnchor" id="H3018325805"><span class="h2">Imaging and lumbar puncture: Indications and safety</span><span class="headingEndMark"> — </span>Indications for neuroimaging and lumbar puncture are similar to those in nonpregnant adults. (See  <a class="medical medical_review" href="/z/d/html/3349.html" rel="external">"Evaluation of headache in adults", section on 'Indications for imaging'</a> and  <a class="medical medical_review" href="/z/d/html/3349.html" rel="external">"Evaluation of headache in adults", section on 'Lumbar puncture'</a>.)</p><p>The choice of imaging modality should be determined by the suspected pathology, with the following considerations:</p><p class="bulletIndent1"><span class="glyph">●</span>Magnetic resonance imaging (MRI) does not expose the fetus to ionizing radiation and has not been associated with adverse fetal effects. Use of gadolinium should be avoided unless its use significantly improves diagnostic performance and is likely to improve patient outcome, as gadolinium may have adverse effects on offspring. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients", section on 'Magnetic resonance imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Computed tomography (CT) involves ionizing radiation, but fetal radiation exposure from scatter is minimal during maternal head CT [<a href="#rid14">14</a>]. Iodinated contrast materials cross the placenta and can produce transient effects on the developing fetal thyroid gland; however, clinical sequelae from brief exposures have not been reported. Iodinated contrast materials should be used in pregnancy, when clinically indicated. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients", section on 'Fetal risks'</a> and  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients", section on 'Use of iodinated contrast materials'</a>.)</p><p></p><p>Lumbar puncture is not contraindicated during pregnancy and should be performed following neuroimaging if increased intracranial pressure or infection is suspected. Neuroimaging is performed to exclude the presence of a large space-occupying lesion, which would be a contraindication to performing a lumbar puncture in the setting of increased intracranial pressure. (See  <a class="medical medical_review" href="/z/d/html/4832.html" rel="external">"Lumbar puncture: Technique, contraindications, and complications in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1285.html" rel="external">"Cerebrospinal fluid: Physiology and utility of an examination in disease states"</a>.)</p><p class="headingAnchor" id="H1276454689"><span class="h1">APPROACH TO TREATMENT</span></p><p class="headingAnchor" id="H4193623659"><span class="h2">General principles</span></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of headaches is indicated for maternal comfort. No large trials of headache therapy in pregnancy are available to provide data on which to base therapeutic recommendations. The major consideration is to "do no harm" since headaches do not appear to adversely affect pregnancy outcome [<a href="#rid15">15-17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs known to be teratogenic or otherwise potentially harmful in pregnancy (eg, uterotonic agents, vasoconstrictors) should be avoided. After exclusion of these drugs, treatment decisions are made according to recommendations for nonpregnant adults, but choosing those drugs with the best safety profile for the fetus and limiting the number of medications and doses to the minimum needed to control symptoms adequately. Treatment is also guided by the woman's prior treatment successes and failures, comorbid conditions, and gestational age (first trimester [ie, after the major period of organogenesis] versus later in pregnancy). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should have realistic expectations regarding the limits of therapy, and clinicians should be willing to treat headache pain aggressively when the patients requests aggressive treatment after a discussion of the available information about potential fetal risks.</p><p></p><p class="headingAnchor" id="H3664489059"><span class="h2">Patients with preeclampsia</span><span class="headingEndMark"> — </span>The definitive treatment of preeclampsia is delivery to prevent development of maternal or fetal complications from disease progression. Antihypertensive therapy should be initiated to reduce severe blood pressure elevation and prevent stroke. <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">Magnesium sulfate</a> is administered to prevent a first or recurrent eclamptic seizures. Preeclampsia-related headache can usually be relieved with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. (See  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients"</a> and  <a class="medical medical_review" href="/z/d/html/1662.html" rel="external">"Eclampsia", section on 'Prevention of recurrent seizures'</a> and  <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Seizure prophylaxis'</a>.)</p><p class="headingAnchor" id="H2302263453"><span class="h2">Postpartum patients</span><span class="headingEndMark"> — </span>Non-breastfeeding postpartum patients are treated with the same drugs as nonpregnant adults, guided by the underlying cause of the headache. </p><p>In breastfeeding patients, medications that are transferred into breast milk and considered potentially harmful to the infant are avoided (eg, in the nursing infant, <a class="drug drug_general" data-topicid="9416" href="/z/d/drug information/9416.html" rel="external">ergotamine</a> may cause vomiting, diarrhea, weakness, and unstable blood pressure, and <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> may cause central nervous system depression). The American College of Obstetricians and Gynecologists advises a shared decision-making model regarding the need to avoid breastfeeding for a specified timeframe after use of triptans (8 to 12 hours after <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">sumatriptan</a> use and 24 hours after use of other triptans) and recommends against use of combination products containing butalbital, medications containing opioids (codeine, <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">hydrocodone</a>, <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>), and ergot alkaloids [<a href="#rid18">18</a>].</p><p>The safety of medication use in breastfeeding mothers can be checked by searching on the drug name in the UpToDate drug information database or by searching on the drug name in other resources, such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK501922%2F%3Freport%3Dclassic&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trxbRM9n9k9jxarxPZM5TS5htB9tQgQ%2BhkEZ6u8L6V76cKfsHR1IKbAngeDe8Jfsj0k%3D&amp;TOPIC_ID=4797" target="_blank">LactMed</a>.</p><p class="headingAnchor" id="H516899303"><span class="h2">Postdural puncture headache</span><span class="headingEndMark"> — </span>Postdural puncture headache is often treated with a blood patch; breastfeeding is not a contraindication. Prophylactic epidural blood patch after unintentional dural puncture has been performed for the prevention of postdural puncture headache. (See  <a class="medical medical_review" href="/z/d/html/113316.html" rel="external">"Post dural puncture headache", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2136219742"><span class="h1">MIGRAINE</span></p><p class="headingAnchor" id="H4082390414"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>Migraine is often, but not always, unilateral and tends to have a throbbing or pulsatile quality. Accompanying features may include nausea, vomiting, and photophobia or phonophobia during attacks. Triggering factors include stress, visual stimuli, weather changes, nitrates, fasting, sleep disturbances, and certain foods. (See  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Diagnosis'</a>.)</p><p>Approximately 18 percent of females in the United States suffer from migraine headaches; many others have mild to moderate interference with their usual activities [<a href="#rid19">19</a>]. The prevalence of migraine in females peaks during the childbearing years. Approximately 2 percent of females develop their first migraine during pregnancy, usually in the first trimester [<a href="#rid20">20</a>]. </p><p>A migraine occurring during pregnancy can generally be differentiated from a preeclampsia-related headache by assessment of the patient's blood pressure, urine protein, laboratory studies, gestational age, and whether she reports similar headaches prior to pregnancy. (See <a class="local">'Patients ≥20 weeks of gestation (evaluate for preeclampsia)'</a> above.)</p><p class="headingAnchor" id="H2505468086"><span class="h2">Course in pregnancy</span><span class="headingEndMark"> — </span>The occurrence of migraine is modulated by fluctuations in estrogen levels (see  <a class="medical medical_review" href="/z/d/html/5441.html" rel="external">"Estrogen-associated migraine headache, including menstrual migraine", section on 'Pathophysiology of estrogen impacting migraine headache'</a>). Most patients (60 to 70 percent) with a history of migraine report improvement over the course of pregnancy, approximately 5 percent describe worsening, and the remainder report no change [<a href="#rid15">15</a>]. Improvement is most likely in those with menstrual migraine, migraine without aura, and patients who experience improvement in the first trimester [<a href="#rid15">15</a>]. Improvement has been defined as absence of attacks, less severe attacks, decreased frequency of attacks, or shorter duration of symptoms.</p><p>The most common time for recurrence is postpartum. Patients with menstrual migraine are most likely to experience postpartum migraine, and those who breastfeed are less likely to experience migraine postpartum [<a href="#rid21">21-24</a>]. In a study of 49 postpartum patients with a history of migraine, migraine recurred during the first week postpartum in 34 percent and during the first postpartum month in 55 percent [<a href="#rid21">21</a>]. The prevalence of migraine in patients who breastfed and bottle-fed was 43 and 100 percent, respectively. The protective effect of breastfeeding, which has also been observed in other studies [<a href="#rid25">25</a>], has been attributed to more stable levels of estrogen in these individuals [<a href="#rid15">15</a>].</p><p>There appears to be an increased risk of stroke associated with migraine, particularly in patients who have migraine with aura. Stroke is also more common postpartum than during a six-week interval in a comparably aged nonpregnant adult female [<a href="#rid26">26,27</a>]. In a study that used discharge codes to evaluate risk factors for stroke in pregnancy and the puerperium, there appeared to be a strong association (odds ratio [OR] 16) between migraine and pregnancy/postpartum stroke [<a href="#rid28">28,29</a>]. The strong association may reflect the increased likelihood of accurately coding migraine in patients who have had a stroke and in the minority of patients whose migraines have been particularly active during pregnancy or postpartum. (See  <a class="medical medical_review" href="/z/d/html/3344.html" rel="external">"Migraine-associated stroke: risk factors, diagnosis, and prevention", section on 'Female sex'</a> and  <a class="medical medical_review" href="/z/d/html/1108.html" rel="external">"Cerebrovascular disorders complicating pregnancy"</a>.)</p><p class="headingAnchor" id="H857002014"><span class="h2">Pregnancy outcome</span><span class="headingEndMark"> — </span>Studies evaluating pregnancy outcome in migraineurs generally conclude that migraines, treated or untreated, are associated with an increased prevalence of hypertensive disorders of pregnancy [<a href="#rid30">30-32</a>]. As an example, in a nationwide, population-based cohort study comparing nearly 23,000 gravid patients with migraines with over 228,000 matched controls, migraine was associated with a 50 percent increase in the adjusted prevalence ratio for hypertensive disorders of pregnancy [<a href="#rid30">30</a>]. Miscarriage, preterm birth, and low birth weight were more modestly increased, and no increase in growth restriction or congenital anomalies was observed. Offspring had a disproportionate increase in short-term morbidities including admission to the neonatal intensive care unit and respiratory distress syndrome, as well as an increase in febrile seizures and epilepsy that persisted during the first year of life. Of note, patients with migraines had higher preconception levels of hypertension, depression, and asthma. (See  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6805.html" rel="external">"Gestational hypertension"</a>.)</p><p>The Nurses' Health Study included over 30,000 incident pregnancies among over 19,000 individuals of whom 2234 had self-reported physician-diagnosed migraine before pregnancy [<a href="#rid32">32</a>]. In this study, migraine was associated with a 40 percent higher risk of preeclampsia (term more than preterm) and a 28 percent higher risk of gestational hypertension compared with no migraine, after adjustment for multiple confounders, and migraine with aura increased the risk more than migraine without aura. Migraine was also associated with a 17 percent increase in preterm birth that persisted when only normotensive pregnancies were analyzed, but not associated with an increased risk of gestational diabetes.</p><p class="headingAnchor" id="H3"><span class="h2">Acute migraine treatment</span><span class="headingEndMark"> — </span>The treatment of migraine in pregnancy differs somewhat from treatment of nonpregnant females because of concerns about adverse fetal drug effects. We begin with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> because it has the best maternal-fetal safety profile. If ineffective, we move on to other drugs in the order listed below. Patients with migraine that has not responded to oral drugs after several days should be evaluated for provoking factors and treated more aggressively. (See  <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">"Acute treatment of migraine in adults"</a>.)</p><p class="headingAnchor" id="H711083317"><span class="h3">First-line therapy: Acetaminophen alone or combination therapy</span><span class="headingEndMark"> — </span>We initiate therapy with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. Acetaminophen (1000 mg orally) can be an effective treatment of migraine [<a href="#rid33">33</a>], and data from large case series show no clear evidence of an increased risk of adverse effects on pregnancy or the fetus. These data are reviewed separately (see  <a class="medical medical_review" href="/z/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs", section on 'Acetaminophen'</a>). Non-oral preparations are available.</p><p>Migraine that does not respond to <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> alone may be relieved with oral combination therapy such as:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a> 650 to 1000 mg and <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> 10 mg </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9251" href="/z/d/drug information/9251.html" rel="external">Acetaminophen-codeine</a> (various formulations are available)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8822" href="/z/d/drug information/8822.html" rel="external">Butalbital-acetaminophen-caffeine</a> (various formulations are available)</p><p></p><p>Butalbital should be limited to only four to five days per month and <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> to no more than nine days per month to avoid development of medication overuse headache. The American College of Obstetricians and Gynecologists advises against the use of butalbital during pregnancy due to inconclusive data with regards to risk of teratogenicity and neonatal addiction; however, in practice, we have found the combination of <a class="drug drug_general" data-topicid="8822" href="/z/d/drug information/8822.html" rel="external">butalbital-acetaminophen-caffeine</a> to be quite effective in the treatment of refractory migraine if <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> alone is not successful in resolving the headache. Its use in the first trimester should be discussed with shared decision-making.</p><p>These medications are generally safe for the fetus.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">Caffeine</a> doses in medications for migraine range from 40 to 50 mg; daily caffeine intake less than 200 mg from all sources is unlikely to be associated with adverse pregnancy effects. (See  <a class="medical medical_review" href="/z/d/html/406.html" rel="external">"Caffeine: Effects on reproductive outcomes in females", section on 'Effects of caffeine on reproductive outcomes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged use of butalbital or <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> near term can cause neonatal withdrawal [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged use of barbiturates can cause vitamin K responsive bleeding in the neonate, but prophylactic vitamin K1 (phytonadione) is routinely given to all newborns in the United States shortly after birth to prevent vitamin K deficient bleeding. Butalbital has not been associated with an increased risk of congenital anomalies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The safety of short-term opioid use in the first trimester is unclear. Limited epidemiologic data have shown an association with nervous system malformations in offspring. (See  <a class="medical medical_review" href="/z/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs", section on 'Opioids'</a>.)</p><p></p><p class="headingAnchor" id="H2676370428"><span class="h3">Second-line therapy: Aspirin or nonsteroidal anti-inflammatory drugs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> and nonsteroidal anti-inflammatory drugs, such as <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a>, and <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a>, are second-line options and are safest in the second trimester before 20 weeks. Non-oral preparations are available (eg, ketorolac 30 mg intravenously once). In the first trimester, a possible modest increase in early pregnancy loss and some congenital anomalies has been suggested, but available evidence is limited and weak. From 20 to approximately 30 weeks, fetal renal effects leading to oligohydramnios are a concern, generally after days to weeks of treatment; treatment &lt;48 hours is generally safe. After 30 weeks, use should be avoided or limited to fewer than 48 hours due to concerns about prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios and its sequelae, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage. (See  <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">"Inhibition of acute preterm labor", section on 'Fetal side effects'</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p class="headingAnchor" id="H3763084842"><span class="h3">Third-line therapies</span></p><p class="headingAnchor" id="H314499"><span class="h4">Opioids</span><span class="headingEndMark"> — </span>Opioids (eg, <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">hydrocodone</a>, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>) are a third-tier option. If used, use of all opioids should be limited to the lowest effective dose and prescribed for the shortest time required to control acute pain. These drugs should not be used on a chronic basis since they are addictive and can contribute to the development of medication overuse and chronic daily headaches [<a href="#rid35">35,36</a>]. They may also worsen the nausea/vomiting and constipation associated with pregnancy. All opioids have potential for maternal addiction and neonatal withdrawal. As discussed above, limited epidemiologic data have shown an association with nervous system malformations in offspring. </p><p>In postpartum breastfeeding patients, an additional consideration is that alterations in metabolism of some drugs (eg, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>) can occur due to genetic variations in cytochrome CYP2D6. This can result in high serum metabolite levels (ultrarapid metabolizers) with potential transfer of these active metabolites into maternal milk, causing excessive infant sedation and fatal overdoses in extreme cases. (See  <a class="medical medical_review" href="/z/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs", section on 'Opioids'</a> and  <a class="medical medical_review" href="/z/d/html/6711.html" rel="external">"Overview of the postpartum period: Normal physiology and routine maternal care", section on 'Safety of common analgesics in breastfeeding individuals'</a>.)</p><p class="headingAnchor" id="H314506"><span class="h4">Triptans</span><span class="headingEndMark"> — </span>For moderate to severe symptoms in patients who do not respond to other drugs, triptans can be considered [<a href="#rid37">37</a>]. <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">Sumatriptan</a> (50 to 100 mg orally, 4 to 6 mg subcutaneously, or 5 to 20 mg intranasal solution) and <a class="drug drug_general" data-topicid="10243" href="/z/d/drug information/10243.html" rel="external">rizatriptan</a> are two selective serotonin agonists that are highly effective in treating migraine headaches. They selectively vasoconstrict brain vessels, but there is a theoretic possibility of vasoconstriction of uteroplacental vessels and increased uterotonic activity [<a href="#rid38">38</a>]. Other triptans can also be used, but <a class="drug drug_general" data-topicid="8693" href="/z/d/drug information/8693.html" rel="external">frovatriptan</a> and <a class="drug drug_general" data-topicid="10167" href="/z/d/drug information/10167.html" rel="external">naratriptan</a> are less desirable than other triptans because of their longer half-life, and naratriptan is the least effective triptan. Preparations and dosing are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">"Acute treatment of migraine in adults", section on 'Triptans'</a>.)</p><p>Human experience with triptan exposure during pregnancy primarily involves <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">sumatriptan</a> and has been generally reassuring [<a href="#rid34">34,39,40</a>]. A manufacturer's pregnancy registry for sumatriptan exposure during pregnancy did not find an increased risk of congenital anomalies or early pregnancy loss in 600 exposed pregnant patients, including 514 first-trimester exposures [<a href="#rid34">34</a>]. The pregnancy registry was closed in 2012; additional information may be obtained from the manufacturer (800-336-2176). In a 2015 systematic review of pregnancy outcome following prenatal exposure to triptans (6 studies, 4208 infants), triptan-exposed migraineurs had similar rates of major congenital anomalies, preterm birth, and early pregnancy loss as migraineurs not using triptans [<a href="#rid39">39</a>]. When the triptan-exposed group was compared with the healthy controls, rates of major congenital anomalies and preterm birth were similar, but early pregnancy loss was increased.</p><p class="headingAnchor" id="H1821297509"><span class="h3">Drugs to reduce nausea and vomiting</span><span class="headingEndMark"> — </span>The H1 antagonists <a class="drug drug_general" data-topicid="9597" href="/z/d/drug information/9597.html" rel="external">meclizine</a> (25 mg orally), <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> (25 to 50 mg orally or 10 to 50 mg intravenously), and <a class="drug drug_general" data-topicid="9820" href="/z/d/drug information/9820.html" rel="external">promethazine</a> (12.5 to 25 mg orally, per rectum, or intramuscularly) are preferred in pregnancy to relieve nausea and vomiting associated with migraine or migraine therapy. </p><p>Dopamine antagonists such as <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> (10 mg intravenously, intramuscularly, or orally) or phenothiazines such as <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a> (10 mg intravenously, intramuscularly, or orally) or <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a> (25 to 50 mg intramuscularly) are effective, but maternal acute dystonic reactions sometimes occur. </p><p>As an alternative, <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> (4 to 8 mg orally or intravenously), a 5HT3 antagonist, may be used to treat severe nausea and vomiting associated with severe migraine headaches. </p><p>The safety profiles of all of these drugs and other anti-emetics used in pregnancy are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6811.html" rel="external">"Nausea and vomiting of pregnancy: Treatment and outcome"</a>.)</p><p class="headingAnchor" id="H2426599264"><span class="h3">Drugs to avoid</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ergotamine</strong> is <strong>absolutely contraindicated</strong> <strong>during pregnancy</strong> because of the potential to induce hypertonic uterine contractions and vasospasm/vasoconstriction, which could cause adverse fetal effects. Postpartum use is reasonable; contraindications are the same as for nonpregnant adults (eg, hypertension; concurrent use of protease inhibitors, azole antifungals, and some macrolide antibiotics).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isometheptene</strong> is a sympathomimetic amine that is used for relief of migraine and tension-type headaches. It is sold in combination with dichloralphenazone and <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. There is no information on its use in pregnancy and other alpha adrenergic agents have been shown to compromise uterine blood flow; therefore, it should be avoided.</p><p></p><p class="headingAnchor" id="H1222254704"><span class="h3">Nonpharmacologic interventions</span><span class="headingEndMark"> — </span>Nonpharmacologic interventions include heat, ice, massage, rest, avoiding triggers (eg, maintaining a regular meal and sleep pattern), and behavioral therapy (eg, relaxation training, biofeedback, cognitive behavioral therapy) [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'Lifestyle measures'</a> and  <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'Nonpharmacologic interventions'</a> and  <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Precipitating and exacerbating factors'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Refractory migraine treatment</span></p><p class="headingAnchor" id="H308831818"><span class="h3">First-line therapy</span><span class="headingEndMark"> — </span>For management of severe, refractory migraine, our preference is a combination of intravenous hydration, an antiemetic (eg, <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a> 10 mg), and an intravenous opioid [<a href="#rid42">42,43</a>]. We suggest pretreatment with 12.5 mg of <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> to avoid akathisia.</p><p class="headingAnchor" id="H1850442573"><span class="h3">Second-line therapy</span><span class="headingEndMark"> — </span>Combination therapy with a triptan and <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">droperidol</a> (2.5 mg intravenously every 30 minutes up to three doses) appears to be effective, but can be associated with extrapyramidal symptoms [<a href="#rid44">44</a>]. Droperidol has no proven teratogenic effects [<a href="#rid34">34</a>]; however, droperidol has been associated with maternal QTc prolongation and the development of torsades de pointes [<a href="#rid45">45</a>]. </p><p class="headingAnchor" id="H2241658757"><span class="h3">Third-line therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnesium sulfate</strong> – The authors sometimes administer <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">magnesium sulfate</a> in the setting of refractory migraine given its safety in pregnancy and personal observations of clinical success. Although the safety of short courses (&lt;5 consecutive days) of magnesium sulfate is well established in pregnancy, its efficacy for treatment of acute migraine in adults has not been clearly established, with conflicting findings among studies. In a 2014 meta-analysis of five randomized trials totaling 295 adults with acute migraine, magnesium treatment (1 or 2 g intravenously over 10 to 15 minutes) resulted in no statistically significant benefit in relief from headache or need for rescue analgesic medications compared with control patients receiving placebo, <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>, or <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a> [<a href="#rid46">46</a>]. However, the trials were underpowered to detect significant differences in these endpoints and generally of poor methodologic quality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – Glucocorticoids may be useful in intractable cases [<a href="#rid47">47,48</a>]. <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> (20 mg orally four times daily for two days) or <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (4 mg orally, 21 tablets over six days) are the preferred glucocorticoids because they are metabolized to inactive forms by the placenta and thus have minimal fetal effects, whereas <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> are metabolically active in the fetus [<a href="#rid48">48</a>]. Some older epidemiologic data suggest a possible association between first-trimester use of glucocorticoids and cleft lip and/or palate, while more recent data do not. (See  <a class="medical medical_review" href="/z/d/html/6769.html" rel="external">"Etiology, prenatal diagnosis, obstetric management, and recurrence of cleft lip and/or palate", section on 'Environmental factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral nerve block</strong> – Peripheral nerve blocks may also be effective. In a series of 13 pregnant patients with migraine refractory to medication, injection of local anesthetic into one or more peripheral nerves (eg, occipital, auriculotemporal, supraorbital, supratrochlear) resulted in elimination of pain in seven, pain reduction in two, and no response in four [<a href="#rid49">49</a>]. Six patients received a single injection; the other seven received two to five sequential nerve blocks. There were no adverse maternal or fetal effects. In a randomized trial of 62 pregnant patients with headache and pain score &gt;3 on the visual rating scale (VRS), occipital nerve block resulted in more patients with VRS scores ≤3 at one hour than standard care of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a> (58 versus 32 percent) and also increased the proportion of patients who left triage within one hour of the block as a result of headache resolution (58 versus 32 percent) [<a href="#rid50">50</a>]. Additional studies should be performed to better define the efficacy of this approach.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Preventive therapies</span><span class="headingEndMark"> — </span>Patients with frequent migraine headaches often benefit from preventive therapy. The most common approach is daily use of beta blockers or calcium channel blockers in the lowest effective dose, and cognitive and behavioral therapy. Comanagement with a neurologist is essential in these difficult cases. The preventive treatment of migraine is reviewed in detail elsewhere (see  <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults"</a>). Specific considerations relating to pregnancy are discussed below:</p><p>First-line preventive therapies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers</strong> such as <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>, and <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> are not teratogens, but fetal/neonatal effects from beta blockade are possible with prolonged use and include mild fetal growth restriction and mild transient neonatal bradycardia, respiratory depression, hyperbilirubinemia, and/or hypoglycemia. Growth restriction may be more of an issue with atenolol than with other beta blockers. (See  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Beta blockers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short- and long-acting</strong> <strong>calcium channel blockers</strong> are commonly used for treatment of hypertension and preterm labor without adverse fetal/pregnancy effects. An increase in congenital anomalies has not been reported in humans, although information is limited [<a href="#rid34">34</a>]. <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">Verapamil</a> is the preferred agent because it is relatively safe and has good tolerability and ease of use. (See  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Calcium channel blockers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyproheptadine</strong> is an older antihistamine agent sometimes used as a preventive therapy and does not appear to have adverse pregnancy effects.</p><p></p><p>Second-line preventive therapies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-dose antidepressants</strong>, such as the serotonin-norepinephrine reuptake inhibitor (SNRI) <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>, or tricyclic antidepressants (TCA), may be considered in refractory patients, particularly those with suspected underlying chronic depressive illness or postpartum depression. Antidepressants have not been clearly associated with an increased risk of congenital anomalies, but can have neonatal effects when taken in the third trimester. The risks of these drugs in pregnant and breastfeeding patients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/89067.html" rel="external">"Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/100334.html" rel="external">"Antenatal use of antidepressants and risks of teratogenicity and adverse pregnancy outcomes: Drugs other than selective serotonin reuptake inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> is an option for refractory patients. Some anticonvulsants, particularly <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, are teratogenic and should be avoided [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Choice of antiseizure medication'</a>.)</p><p></p><p>Other:</p><p class="bulletIndent1"><span class="glyph">●</span>Although there are no studies reviewing their use in pregnancy, nutraceuticals may be considered for migraine prophylaxis. The most commonly used are magnesium 400 to 800 mg daily, <a class="drug drug_general" data-topicid="9861" href="/z/d/drug information/9861.html" rel="external">riboflavin</a> 400 mg daily, or extract of butterbur root 50 to 100 mg twice daily.</p><p></p><p class="headingAnchor" id="H6"><span class="h1">TENSION-TYPE HEADACHE</span></p><p class="headingAnchor" id="H122820878"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>Tension-type headaches are the most common type of headache. They are characterized by feelings of pressure or tightness all around the head, and have a tendency to wax and wane in intensity. Gastrointestinal upset and heightened sensitivity to light, sound, and smell may occur, but are more typical of migraine [<a href="#rid52">52</a>]. Tension-type headaches had been attributed to muscle aches from psychological stress. (See  <a class="medical medical_review" href="/z/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis", section on 'Etiology'</a>.)</p><p class="headingAnchor" id="H2108220402"><span class="h2">Course in pregnancy</span><span class="headingEndMark"> — </span>In contrast to migraine, the frequency of tension-type headaches usually does not change during pregnancy since these headaches are not hormonally mediated. In two small studies, 56 and 67 percent of patients reported no change in tension headache frequency during pregnancy, 40 and 28 percent reported improvement, and 4 and 5 percent reported worsening [<a href="#rid53">53,54</a>].</p><p class="headingAnchor" id="H337428137"><span class="h2">Pregnancy outcome</span><span class="headingEndMark"> — </span>The only study that evaluated pregnancy outcome in patients with tension-type headache reported an increased risk of preterm birth (8.7 versus 2.8 percent in controls without headache), but this was likely due to chance given the unusually low rate of preterm birth in the control group [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Drug treatment</span><span class="headingEndMark"> — </span>The acute treatment of tension-type headache in adults is similar in pregnant and nonpregnant patients, and is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3358.html" rel="external">"Tension-type headache in adults: Acute treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>First- and second-line therapies</strong> – <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a> is the first-line analgesic for treatment of tension-type headaches during pregnancy, and a short course of nonsteroidal anti-inflammatory drugs (NSAIDs) is a second-line medical therapy, with the caveats described above. (See <a class="local">'First-line therapy: Acetaminophen alone or combination therapy'</a> above and <a class="local">'Second-line therapy: Aspirin or nonsteroidal anti-inflammatory drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Third-line therapies</strong> – If monotherapy is ineffective, a combination of <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> 500 mg and <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a> 100 mg is a reasonable third tier.</p><p></p><p class="bulletIndent1">Butalbital and <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> may be considered when other drugs have been ineffective or NSAIDs are contraindicated (eg, the third trimester of pregnancy), but prolonged use should be avoided due to the potential for drug dependency and medication overuse headaches. Butalbital should be limited to only four to five days per month and codeine to no more than nine days per month to avoid development of medication overuse headaches.</p><p></p><p class="headingAnchor" id="H1523595907"><span class="h2">Nonpharmacologic interventions</span><span class="headingEndMark"> — </span>Nonpharmacologic interventions include heat, ice, massage, rest, avoiding triggers (eg, maintaining a regular meal and sleep pattern), and behavioral therapy (eg, relaxation training, biofeedback, cognitive behavioral therapy) [<a href="#rid41">41</a>]. Physical therapy also may reduce the frequency of headaches in some patients.</p><p class="headingAnchor" id="H8"><span class="h1">CLUSTER HEADACHE</span></p><p class="headingAnchor" id="H702983577"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>Cluster headache is a repetitive headache that occurs for weeks to months at a time, followed by periods of remission. The pain begins quickly, reaches a crescendo within a few minutes, and is usually excruciating. It is always unilateral and associated with cranial autonomic symptoms, such as nasal stuffiness, lacrimation, facial sweating, or eyelid edema. (See  <a class="medical medical_review" href="/z/d/html/3326.html" rel="external">"Cluster headache: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3084632261"><span class="h2">Course in pregnancy</span><span class="headingEndMark"> — </span>Cluster headache is probably not affected by reproductive hormonal changes [<a href="#rid56">56-58</a>]. In a study that examined the clinical features of headache and the physiologic events related to reproductive life in 82 females with these headaches compared with a control group, the course of cluster headache was not altered by menstruation, pregnancy, or the puerperium [<a href="#rid56">56</a>]. However, other studies have reported improvement. In one such study, 6 of 8 females with a history of cluster headache who became pregnant reported remission during their 9 pregnancies [<a href="#rid59">59</a>] and another noted that 3 of 58 females with a history of cluster headache commented that they were due for a bout of headaches when they became pregnant, but missed the bout [<a href="#rid60">60</a>]. In one subject, the bout started postpartum after two pregnancies.</p><p class="headingAnchor" id="H3027899900"><span class="h2">Pregnancy outcome</span><span class="headingEndMark"> — </span>The effect of cluster headache on pregnancy outcome has not been described.</p><p class="headingAnchor" id="H9"><span class="h2">Treatment</span></p><p class="headingAnchor" id="H3241963919"><span class="h3">First- and second-line therapies</span><span class="headingEndMark"> — </span>First- and second-line therapies (oxygen, triptans) are similar to those in nonpregnant adults [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/z/d/html/3351.html" rel="external">"Cluster headache: Treatment and prognosis"</a>.)</p><p>Abortive therapy of cluster headache can be difficult because of the short duration of each episode. In most patients, acute cluster headache can be aborted by inhalation of 100 percent oxygen. If unsuccessful, subcutaneous or intranasal <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">sumatriptan</a> is a reasonable option. As discussed above (see <a class="local">'Triptans'</a> above), human experience with sumatriptan exposure in several hundred pregnancies has been reassuring.</p><p class="headingAnchor" id="H3694091436"><span class="h4">Topical lidocaine</span><span class="headingEndMark"> — </span>If response to these therapies is suboptimal, 0.5 mL <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> 4% can be placed inside the nostril on the affected side of the head; extensive experience with local anesthesia in pregnancy suggests that it is not associated with significant adverse reproductive or teratogenic effects [<a href="#rid34">34</a>]. </p><p class="headingAnchor" id="H2332935797"><span class="h3">Drugs to avoid</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9416" href="/z/d/drug information/9416.html" rel="external">Ergotamine</a> is effective but <strong>absolutely contraindicated</strong> <strong>during pregnancy</strong> because of the potential to induce hypertonic uterine contractions and vasospasm/vasoconstriction, which could cause adverse fetal effects. Postpartum use in non-breastfeeding patients is reasonable; contraindications are the same as for nonpregnant adults (eg, hypertension; concurrent use of protease inhibitors, azole antifungals, and some macrolide antibiotics). Because of limited published experience with ergotamine during breastfeeding and the potential for adverse effects in the infant, we avoid its use in nursing patients.</p><p class="headingAnchor" id="H3469141354"><span class="h3">Preventive therapy</span></p><p class="headingAnchor" id="H3194567352"><span class="h4">First-line therapies</span><span class="headingEndMark"> — </span>When preventive therapy is indicated, the two best options during pregnancy are <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> and glucocorticoids [<a href="#rid61">61</a>].</p><p><a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">Verapamil</a> is the preferred calcium channel blocker because it is relatively safe and has good tolerability and ease of use. The starting dose is usually 240 mg daily in three divided doses. Most patients respond to a total dose of 240 to 320 mg daily. Titration to a total dose of up to 960 mg daily may be necessary for some patients to obtain full prophylactic benefit (see  <a class="medical medical_review" href="/z/d/html/3351.html" rel="external">"Cluster headache: Treatment and prognosis", section on 'Verapamil plus glucocorticoids for patients with frequent attacks'</a>). As discussed above, short- and long-acting calcium channel blockers are commonly used for treatment of hypertension and preterm labor, without adverse fetal/pregnancy effects. An increase in congenital anomalies has not been reported in humans, although information is limited [<a href="#rid34">34</a>].</p><p><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> (20 mg orally four times daily for two days) and <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (4 mg orally, 21 tablets over six days) are the preferred glucocorticoids because they are metabolized to inactive forms by the placenta and have minimal fetal effects, whereas <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> are metabolically active in the fetus [<a href="#rid48">48</a>]. Some older epidemiologic data suggest a possible association between first-trimester use of glucocorticoids and cleft lip and/or palate, while more recent data do not. (See  <a class="medical medical_review" href="/z/d/html/3351.html" rel="external">"Cluster headache: Treatment and prognosis", section on 'Glucocorticoids for patients with infrequent attacks'</a> and  <a class="medical medical_review" href="/z/d/html/6769.html" rel="external">"Etiology, prenatal diagnosis, obstetric management, and recurrence of cleft lip and/or palate", section on 'Environmental factors'</a>.)</p><p class="headingAnchor" id="H1598745879"><span class="h4">Second-line therapies</span><span class="headingEndMark"> — </span>After the first trimester, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> are options. (See  <a class="medical medical_review" href="/z/d/html/3351.html" rel="external">"Cluster headache: Treatment and prognosis", section on 'Lithium'</a> and  <a class="medical medical_review" href="/z/d/html/3351.html" rel="external">"Cluster headache: Treatment and prognosis", section on 'Topiramate'</a>.)</p><p>First-trimester fetal exposure to <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> has been associated with Ebstein's anomaly, and third-trimester exposure has been associated with signs of lithium toxicity in neonates. (See  <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'</a>.)</p><p>First-trimester exposure to <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> has been associated with cleft lip and/or palate, so use of the drug should be avoided before anatomic closure (complete closure of the lip is usually accomplished by 35 days postconception and palatal closure is complete by 56 to 58 days postconception) [<a href="#rid34">34</a>]. Use of topiramate during pregnancy has also been associated with low birth weight [<a href="#rid63">63,64</a>]. (See  <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Topiramate'</a>.)</p><p class="headingAnchor" id="H1113331515"><span class="h4">Third-line therapies</span><span class="headingEndMark"> — </span>Third-line agents include <a class="drug drug_general" data-topicid="10091" href="/z/d/drug information/10091.html" rel="external">pizotifen</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, intranasal application of <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a>, oral melatonin [<a href="#rid61">61</a>], and greater occipital nerve block. Pizotifen and gabapentin should not be used in the first trimester because there is only sparse information on fetal effects of gabapentin and pizotifen [<a href="#rid34">34</a>]. There is minimal information on use of capsaicin and melatonin in pregnancy, but short-term use is unlikely to be harmful. (See  <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'</a> and  <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'</a> and  <a class="medical medical_review" href="/z/d/html/3351.html" rel="external">"Cluster headache: Treatment and prognosis", section on 'Other medications'</a>.)</p><p class="headingAnchor" id="H4215202832"><span class="h1">MEDICATION OVERUSE HEADACHE</span><span class="headingEndMark"> — </span>Medication overuse headaches may develop with frequent (daily) use of analgesics, including <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, in patients with recurrent headaches. Medication overuse headaches may be confused with migraine and can develop in patients with migraine; the diagnosis should be suspected in patients who have persistent daily headaches despite the regular use of analgesic medications. The only treatment is cessation of the offending drug. (See  <a class="medical medical_review" href="/z/d/html/3340.html" rel="external">"Medication overuse headache: Etiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3341.html" rel="external">"Medication overuse headache: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H44960582"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients requiring urgent evaluation</strong> – Preeclampsia  (<a class="graphic graphic_table graphicRef79977" href="/z/d/graphic/79977.html" rel="external">table 1</a>) must be ruled in or out in every pregnant woman over 20 weeks of gestation or postpartum with headache. (See <a class="local">'Patients ≥20 weeks of gestation (evaluate for preeclampsia)'</a> above.)</p><p></p><p class="bulletIndent1">Pregnant patients with headache characteristics that may be associated with a serious underlying disorder  (<a class="graphic graphic_table graphicRef112044" href="/z/d/graphic/112044.html" rel="external">table 5</a>), especially if not typical of the patient's usual headache, should be evaluated immediately for an acute neurovascular event  (<a class="graphic graphic_algorithm graphicRef107496" href="/z/d/graphic/107496.html" rel="external">algorithm 1</a>), as well as preeclampsia. (See <a class="local">'Patients with symptoms potentially associated with a serious underlying disorder'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach to evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A patient with a prior history of tension-type headache, migraine headache, or cluster headache may continue to experience headache during pregnancy; pursuing a complicated duplication of diagnostic testing is not necessary if their characteristic symptoms  (<a class="graphic graphic_table graphicRef68064" href="/z/d/graphic/68064.html" rel="external">table 3</a>) have not changed and preeclampsia has been excluded. (See <a class="local">'General approach to evaluating headache in pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among pregnant patients with the onset of new or atypical headache in whom preeclampsia has been excluded, approximately half have migraine and the other half have a variety of other causes of headache  (<a class="graphic graphic_table graphicRef71620" href="/z/d/graphic/71620.html" rel="external">table 2</a>). These women should be evaluated initially with a detailed history and physical examination, similar to that in nonpregnant adults. A general approach to the evaluation of new headache is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef141075" href="/z/d/graphic/141075.html" rel="external">algorithm 2</a>). Clinical features of headaches related to underlying conditions are described in the table  (<a class="graphic graphic_table graphicRef141069" href="/z/d/graphic/141069.html" rel="external">table 4</a>). (See <a class="local">'General approach to evaluating headache in pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Indications for neuroimaging and lumbar puncture are similar to those in nonpregnant adults. If magnetic resonance imaging is performed, use of gadolinium should be avoided as it appears to have adverse effects on offspring. If computed tomography of the head is performed, fetal radiation exposure from scatter is minimal. (See <a class="local">'Imaging and lumbar puncture: Indications and safety'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment during pregnancy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Migraine</strong> – Most patients with migraine headache report improvement during pregnancy. For women who request drug therapy, we suggest <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> as first-line acute (abortive) therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients who do not respond to acetaminophen alone, we suggest acetaminophen combination therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Oral drug options include acetaminophen (650 to 1000 mg) and <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> (10 mg); <a class="drug drug_general" data-topicid="9251" href="/z/d/drug information/9251.html" rel="external">acetaminophen-codeine</a>; or <a class="drug drug_general" data-topicid="8822" href="/z/d/drug information/8822.html" rel="external">butalbital-acetaminophen-caffeine</a>.</p><p></p><p class="bulletIndent2">If unsuccessful, our second-line approach is a nonsteroidal anti-inflammatory drug for &lt;48 hours, followed by third-line options, beginning with an opioid and then moving to <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">sumatriptan</a> if the opioid is unsuccessful or needed frequently. (See <a class="local">'Acute migraine treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tension headache</strong> – The frequency of tension-type headache generally remains stable during pregnancy since it is not hormonally mediated. We recommend <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> as first-line drug therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Nonpharmacologic/behavioral interventions are also useful. (See <a class="local">'Tension-type headache'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cluster headache</strong> – The frequency of cluster headache generally remains stable during pregnancy, since it is not hormonally mediated. In most patients, acute cluster headache can be aborted by inhalation of 100 percent oxygen. If unsuccessful, subcutaneous or intranasal <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">sumatriptan</a> is a reasonable option. (See <a class="local">'Cluster headache'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum patients</strong> – The postpartum period is characterized by multiple changes that increase the risk of developing headache. Differential diagnosis includes primary headache (almost always tension-type or migraine) and secondary causes of headache, including preeclampsia/eclampsia, postdural puncture headache, and cerebral venous thrombosis. The presence of focal neurologic signs usually requires neurologic imaging and consultation with a neurologist to rule out intracranial pathology. (See <a class="local">'Evaluation of postpartum patients'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Aegidius K, Zwart JA, Hagen K, Stovner L. The effect of pregnancy and parity on headache prevalence: the Head-HUNT study. Headache 2009; 49:851.</a></li><li><a class="nounderline abstract_t">Melhado EM, Maciel JA Jr, Guerreiro CA. Headache during gestation: evaluation of 1101 women. Can J Neurol Sci 2007; 34:187.</a></li><li><a class="nounderline abstract_t">Witlin AG, Saade GR, Mattar F, Sibai BM. Risk factors for abruptio placentae and eclampsia: analysis of 445 consecutively managed women with severe preeclampsia and eclampsia. Am J Obstet Gynecol 1999; 180:1322.</a></li><li><a class="nounderline abstract_t">Belfort MA, Saade GR, Grunewald C, et al. Association of cerebral perfusion pressure with headache in women with pre-eclampsia. Br J Obstet Gynaecol 1999; 106:814.</a></li><li><a class="nounderline abstract_t">Schwartz RB, Jones KM, Kalina P, et al. Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 1992; 159:379.</a></li><li><a class="nounderline abstract_t">Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494.</a></li><li><a class="nounderline abstract_t">Cunningham FG, Twickler D. Cerebral edema complicating eclampsia. Am J Obstet Gynecol 2000; 182:94.</a></li><li><a class="nounderline abstract_t">Contag SA, Bushnell C. Contemporary management of migrainous disorders in pregnancy. Curr Opin Obstet Gynecol 2010; 22:437.</a></li><li><a class="nounderline abstract_t">Marcus DA. Managing headache during pregnancy and lactation. Expert Rev Neurother 2008; 8:385.</a></li><li><a class="nounderline abstract_t">Silberstein SD. Evaluation and emergency treatment of headache. Headache 1992; 32:396.</a></li><li><a class="nounderline abstract_t">Goldszmidt E, Kern R, Chaput A, Macarthur A. The incidence and etiology of postpartum headaches: a prospective cohort study. Can J Anaesth 2005; 52:971.</a></li><li><a class="nounderline abstract_t">Stella CL, Jodicke CD, How HY, et al. Postpartum headache: is your work-up complete? Am J Obstet Gynecol 2007; 196:318.e1.</a></li><li><a class="nounderline abstract_t">Vgontzas A, Robbins MS. A Hospital Based Retrospective Study of Acute Postpartum Headache. Headache 2018; 58:845.</a></li><li><a class="nounderline abstract_t">Goldberg-Stein SA, Liu B, Hahn PF, Lee SI. Radiation dose management: part 2, estimating fetal radiation risk from CT during pregnancy. AJR Am J Roentgenol 2012; 198:W352.</a></li><li><a class="nounderline abstract_t">MacGregor EA. Headache in pregnancy. Neurol Clin 2012; 30:835.</a></li><li><a class="nounderline abstract_t">Aromaa M, Rautava P, Helenius H, Sillanpää ML. Prepregnancy headache and the well-being of mother and newborn. Headache 1996; 36:409.</a></li><li><a class="nounderline abstract_t">Dixit A, Bhardwaj M, Sharma B. Headache in pregnancy: a nuisance or a new sense? Obstet Gynecol Int 2012; 2012:697697.</a></li><li><a class="nounderline abstract_t">Headaches in Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 3. Obstet Gynecol 2022; 139:944.</a></li><li><a class="nounderline abstract_t">Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993; 43:S6.</a></li><li><a class="nounderline abstract_t">Ertresvåg JM, Zwart JA, Helde G, et al. Headache and transient focal neurological symptoms during pregnancy, a prospective cohort. Acta Neurol Scand 2005; 111:233.</a></li><li><a class="nounderline abstract_t">Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003; 23:197.</a></li><li><a class="nounderline abstract_t">Silberstein SD. Headaches in pregnancy. Neurol Clin 2004; 22:727.</a></li><li><a class="nounderline abstract_t">Wall VR. Breastfeeding and migraine headaches. J Hum Lact 1992; 8:209.</a></li><li><a class="nounderline abstract_t">Marcus DA, Scharff L, Turk D. Longitudinal prospective study of headache during pregnancy and postpartum. Headache 1999; 39:625.</a></li><li><a class="nounderline abstract_t">Hoshiyama E, Tatsumoto M, Iwanami H, et al. Postpartum migraines: a long-term prospective study. Intern Med 2012; 51:3119.</a></li><li><a class="nounderline abstract_t">Kittner SJ, Stern BJ, Feeser BR, et al. Pregnancy and the risk of stroke. N Engl J Med 1996; 335:768.</a></li><li><a class="nounderline abstract_t">Sharshar T, Lamy C, Mas JL. Incidence and causes of strokes associated with pregnancy and puerperium. A study in public hospitals of Ile de France. Stroke in Pregnancy Study Group. Stroke 1995; 26:930.</a></li><li><a class="nounderline abstract_t">James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005; 106:509.</a></li><li><a class="nounderline abstract_t">Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ 2009; 338:b664.</a></li><li><a class="nounderline abstract_t">Skajaa N, Szépligeti SK, Xue F, et al. Pregnancy, Birth, Neonatal, and Postnatal Neurological Outcomes After Pregnancy With Migraine. Headache 2019; 59:869.</a></li><li><a class="nounderline abstract_t">Crowe HM, Wesselink AK, Hatch EE, et al. Migraine and risk of hypertensive disorders of pregnancy: A population-based cohort study. Cephalalgia 2023; 43:3331024231161746.</a></li><li><a class="nounderline abstract_t">Purdue-Smithe AC, Stuart JJ, Farland LV, et al. Prepregnancy Migraine, Migraine Phenotype, and Risk of Adverse Pregnancy Outcomes. Neurology 2023; 100:e1464.</a></li><li><a class="nounderline abstract_t">Lipton RB, Baggish JS, Stewart WF, et al. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 2000; 160:3486.</a></li><li class="breakAll">www.reprotox.org (Accessed on October 18, 2012).</li><li><a class="nounderline abstract_t">Mathew NT. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin 1997; 15:167.</a></li><li><a class="nounderline abstract_t">Rapoport A, Stang P, Gutterman DL, et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996; 36:14.</a></li><li><a class="nounderline abstract_t">Evans EW, Lorber KC. Use of 5-HT1 agonists in pregnancy. Ann Pharmacother 2008; 42:543.</a></li><li><a class="nounderline abstract_t">Olesen C, Steffensen FH, Sorensen HT, et al. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40:20.</a></li><li><a class="nounderline abstract_t">Marchenko A, Etwel F, Olutunfese O, et al. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache 2015; 55:490.</a></li><li><a class="nounderline abstract_t">Spielmann K, Kayser A, Beck E, et al. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia 2018; 38:1081.</a></li><li><a class="nounderline abstract_t">Penzien DB, Taylor FR. Headache toolbox. Behavioral and other nonpharmacologic treatments for headache. Headache 2014; 54:955.</a></li><li><a class="nounderline abstract_t">Demirkaya S, Vural O, Dora B, Topçuoğlu MA. Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 2001; 41:171.</a></li><li><a class="nounderline abstract_t">Rozen TD. Aborting a prolonged migrainous aura with intravenous prochlorperazine and magnesium sulfate. Headache 2003; 43:901.</a></li><li><a class="nounderline abstract_t">Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. Headache 1997; 37:377.</a></li><li class="breakAll">US Food and Drug Administration. Inapsine (droperidol) Dear Healthcare Professional Letter Dec 2001. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173778.htm (Accessed on June 24, 2011).</li><li><a class="nounderline abstract_t">Choi H, Parmar N. The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials. Eur J Emerg Med 2014; 21:2.</a></li><li><a class="nounderline abstract_t">Lucas S. Medication use in the treatment of migraine during pregnancy and lactation. Curr Pain Headache Rep 2009; 13:392.</a></li><li><a class="nounderline abstract_t">Solomon GD, Cady RK, Klapper JA, Ryan RE Jr. Standards of care for treating headache in primary care practice. National Headache Foundation. Cleve Clin J Med 1997; 64:373.</a></li><li><a class="nounderline abstract_t">Govindappagari S, Grossman TB, Dayal AK, et al. Peripheral nerve blocks in the treatment of migraine in pregnancy. Obstet Gynecol 2014; 124:1169.</a></li><li><a class="nounderline abstract_t">Bushman ET, Blanchard CT, Cozzi GD, et al. Occipital Nerve Block Compared With Acetaminophen and Caffeine for Headache Treatment in Pregnancy: A Randomized Controlled Trial. Obstet Gynecol 2023; 142:1179.</a></li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/ucm350684.htm (Accessed on May 15, 2013).</li><li><a class="nounderline abstract_t">Paulson GW. Headaches in women, including women who are pregnant. Am J Obstet Gynecol 1995; 173:1734.</a></li><li><a class="nounderline abstract_t">Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 1993; 53:65.</a></li><li><a class="nounderline abstract_t">Karlı N, Baykan B, Ertaş M, et al. Impact of sex hormonal changes on tension-type headache and migraine: a cross-sectional population-based survey in 2,600 women. J Headache Pain 2012; 13:557.</a></li><li><a class="nounderline abstract_t">Marozio L, Facchinetti F, Allais G, et al. Headache and adverse pregnancy outcomes: a prospective study. Eur J Obstet Gynecol Reprod Biol 2012; 161:140.</a></li><li><a class="nounderline abstract_t">Manzoni GC, Micieli G, Granella F, et al. Cluster headache in women: clinical findings and relationship with reproductive life. Cephalalgia 1988; 8:37.</a></li><li><a class="nounderline abstract_t">van Vliet JA, Favier I, Helmerhorst FM, et al. Cluster headache in women: relation with menstruation, use of oral contraceptives, pregnancy, and menopause. J Neurol Neurosurg Psychiatry 2006; 77:690.</a></li><li><a class="nounderline abstract_t">Calhoun AH, Peterlin BL. Treatment of cluster headache in pregnancy and lactation. Curr Pain Headache Rep 2010; 14:164.</a></li><li><a class="nounderline abstract_t">Ekbom K, Waldenlind E. Cluster headache in women: evidence of hypofertility(?) Headaches in relation to menstruation and pregnancy. Cephalalgia 1981; 1:167.</a></li><li><a class="nounderline abstract_t">Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 2002; 58:354.</a></li><li><a class="nounderline abstract_t">Jürgens TP, Schaefer C, May A. Treatment of cluster headache in pregnancy and lactation. Cephalalgia 2009; 29:391.</a></li><li><a class="nounderline abstract_t">Giraud P, Chauvet S. Cluster headache during pregnancy: case report and literature review. Headache 2009; 49:136.</a></li><li><a class="nounderline abstract_t">Hernández-Díaz S, Mittendorf R, Smith CR, et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol 2014; 123:21.</a></li><li><a class="nounderline abstract_t">Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 2014; 261:579.</a></li></ol></div><div id="topicVersionRevision">Topic 4797 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19545250" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The effect of pregnancy and parity on headache prevalence: the Head-HUNT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17598596" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Headache during gestation: evaluation of 1101 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10368466" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk factors for abruptio placentae and eclampsia: analysis of 445 consecutively managed women with severe preeclampsia and eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10453832" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Association of cerebral perfusion pressure with headache in women with pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1632361" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559202" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A reversible posterior leukoencephalopathy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10649162" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cerebral edema complicating eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20930632" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Contemporary management of migrainous disorders in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18345969" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Managing headache during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1399562" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evaluation and emergency treatment of headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16251565" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The incidence and etiology of postpartum headaches: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403403" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Postpartum headache: is your work-up complete?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29446070" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A Hospital Based Retrospective Study of Acute Postpartum Headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22451572" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Radiation dose management: part 2, estimating fetal radiation risk from CT during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22840792" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Headache in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8783471" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prepregnancy headache and the well-being of mother and newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22518165" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Headache in pregnancy: a nuisance or a new sense?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35576364" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Headaches in Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8502385" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Migraine in the United States: a review of epidemiology and health care use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15740574" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Headache and transient focal neurological symptoms during pregnancy, a prospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12662187" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Course of migraine during pregnancy and postpartum: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15474764" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Headaches in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1288557" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Breastfeeding and migraine headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279958" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Longitudinal prospective study of headache during pregnancy and postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23154716" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Postpartum migraines: a long-term prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8703181" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pregnancy and the risk of stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7762040" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Incidence and causes of strokes associated with pregnancy and puerperium. A study in public hospitals of Ile de France. Stroke in Pregnancy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135580" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Incidence and risk factors for stroke in pregnancy and the puerperium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19278973" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31069791" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pregnancy, Birth, Neonatal, and Postnatal Neurological Outcomes After Pregnancy With Migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36935588" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Migraine and risk of hypertensive disorders of pregnancy: A population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36657989" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prepregnancy Migraine, Migraine Phenotype, and Risk of Adverse Pregnancy Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112243" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112243" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9058404" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Transformed migraine, analgesic rebound, and other chronic daily headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8666530" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Analgesic rebound headache in clinical practice: data from a physician survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18349309" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Use of 5-HT1 agonists in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10759898" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pregnancy outcome following prescription for sumatriptan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644494" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28758416" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797490" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Headache toolbox. Behavioral and other nonpharmacologic treatments for headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11251702" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940813" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Aborting a prolonged migrainous aura with intravenous prochlorperazine and magnesium sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9237411" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Droperidol treatment of status migrainosus and refractory migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9237411" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Droperidol treatment of status migrainosus and refractory migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23921817" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19728967" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Medication use in the treatment of migraine during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9223767" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Standards of care for treating headache in primary care practice. National Headache Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415168" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Peripheral nerve blocks in the treatment of migraine in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37769308" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Occipital Nerve Block Compared With Acetaminophen and Caffeine for Headache Treatment in Pregnancy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37769308" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Occipital Nerve Block Compared With Acetaminophen and Caffeine for Headache Treatment in Pregnancy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610754" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Headaches in women, including women who are pregnant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8316392" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22935969" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of sex hormonal changes on tension-type headache and migraine: a cross-sectional population-based survey in 2,600 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22280825" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Headache and adverse pregnancy outcomes: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3359483" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cluster headache in women: clinical findings and relationship with reproductive life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16407458" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cluster headache in women: relation with menstruation, use of oral contraceptives, pregnancy, and menopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425207" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of cluster headache in pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7346185" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cluster headache in women: evidence of hypofertility(?) Headaches in relation to menstruation and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11839832" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cluster headache: a prospective clinical study with diagnostic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19170693" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of cluster headache in pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19125883" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cluster headache during pregnancy: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463659" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Association between topiramate and zonisamide use during pregnancy and low birth weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24449062" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
